Results of Meeting and Chairman's Address
Released
Released
Announcement PDF
COMPANY ANNOUNCEMENT
(ASX: ANP)
Results of Annual General Meeting
Thursday, 12th of November 2015
The Company wishes to advise that all resolutions considered from the Notice of Meeting were carried on a
show of hands.
In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following
information is provided in relation to the resolutions considered by Members of the Company at its Annual
General Meeting held on Thursday, 12th of November 2015.
Resolution
For
Against
Abstain
Undirected*
For
Percentage**
1
Non-binding resolution to adopt the
2015 Remuneration Report ***
42,989,673 7,205,880
5,179,259
36,019
85.65%
2
Approve the previous issue of
15,025,075 Shares to Cortendo AB
33,169,449 7,166,863 15,038,500
36,019
82.25%
3
Approval of 10% Placement
Facility***
48,161,161 7,200,226
36,019
87.00%
13,425
* The Chairman voted undirected proxy’s in his control in favour of all resolutions.
** For Percentage includes undirected votes at the control of the Chairman voted in favour.
*** Resolution 1 and 3 are special resolutions and require 75% approval to be passed. This threshold has been achieved and the
resolutions passed.
For and on behalf of the Board;
Mr Robert Moses
Chairman
CHAIRMAN’S ADDRESS TO 2015 AGM
Ladies and Gentleman, I am pleased to report to you that, since we met last year your Company has further
progressed its antisense product portfolio and significantly enhanced the fundamental value of your
company in terms of both its secure current financial condition and importantly the prospect of substantial
future cash flows. In addition to the upfront cash payment received from licensing our ATL1103 acromegaly
product to Nasdaq-listed Strongbridge Biopharma, potential future cash flows from this deal include
milestone payments totaling up to A$ 177 million* and potential for up to double digit royalties. We have
also added significantly to our patent portfolio and substantially strengthened the Board. The Company
also continues to have the support of our partner, Isis Pharmaceuticals who most of you will recognise is
the clear world leader in antisense technology and a major player in the rapidly growing RNA therapeutics
sector. Antisense Therapeutics operates in the same RNA therapeutics sector.
In bringing two new U.S. based Directors onto the Board, Bill Goolsbee and Gary Pace, we are adding
exceptionally strong experience and expertise in the global pharmaceutical industry. This will be particularly
beneficial to ANP with respect to our strategic positioning, partnering and investor interactions in the U.S.
Both Bill and Gary have extensive U.S. capital market and industry connections.
Our Company now has a solid platform to build on, proven science, and two mature Phase II drugs, one of
which is already licensed with the potential to earn substantial future revenue. Accordingly we are
optimistic and confident that the Company’s best days are ahead of us. We have a very good story to tell,
and we are telling it; not only here in Australia, but overseas – in particular the USA – and our story is being
told to both the investment community and the pharmaceutical and biotech industries. I refer you to the
first few pages of our Annual Report for a more comprehensive review of the past years activities and
accomplishments.
I would like to personally thank our Management Team. They have worked tirelessly and tenaciously to
build value in the Company for all shareholders which as you most likely know includes Isis and
Strongbridge as well as the Board and Management.
Finally, on behalf of both Board and Management, I would like to express our appreciation for our many
loyal, long term shareholders who continue to be supportive. Your support is reflected in the proxy voting
and demonstrates that you continue to have confidence that Antisense Therapeutics will deliver the value
you expect and deserve.
Chairman
Subject to A$/USD currency fluctuation
Share your feedback
Discover